Answers are grounded in this paper and cite their sources.
Background: Oncology clinical trials have expanded rapidly in China over the past decade, but concerns remain about whether the distribution of these trials is proportionate to the national cancer disease burden. Previous studies have described oncology trial trends and noted imbalances for certain high-incidence cancers, yet lacked a systematic quantitative assessment of their equity. We aimed to quantify the alignment between oncology clinical trial activity and cancer-specific disease burden in China. We also examined temporal changes in this alignment and differences between industry-sponsored and investigator-initiated trials. Methods: We used disability-adjusted life years as the indicator of disease burden. By calculating the concentration index (CI) and horizontal inequality index (HII) of oncology drug clinical trials in China, we analysed the equity of oncology drug clinical trial development relative to the distribution of disease burden. Results: Between 2014 and 2023, a total of 18,429 oncology clinical trials were conducted in China, with investigator-initiated trials (IITs) constituting the majority (76.1%). Although research efforts were generally concentrated in cancers with a high disease burden (CI = 0.51), the allocation of trials was disproportionately skewed towards lower-burden cancers (HII = -0.17). This misalignment worsened over time (β = -0.010/year, P = 0.002). The inequity was more pronounced in industry-sponsored trials (ISTs) (HII = -0.22) compared to IITs (HII = -0.16). Conclusions: China's oncology drug clinical trials generally showed an upward trend from 2014 to 2023, with substantial variation in trial numbers across different tumour types. Research resource allocation was disproportionately biased towards low-burden tumours, a trend more pronounced in ISTs. These findings suggest that future research policies should incorporate disease-burden alignment into trial prioritisation and funding decisions, particularly by creating targeted public funding streams and regulatory incentives for high-burden but relatively under-studied cancers.
No takes yet. Share an insight, caveat, or question.
Huang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: